Trials / Completed
CompletedNCT00686777
Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)
Low Dose Treatment of Ribavirin in Combination With PEG-IFN Alfa-2b in CHC Patients With genotype1 High Viral Load and Low Body Weight
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to evaluate the efficacy and safety of the combination therapy with subcutaneous (SC) Pegylated Interferon (PEG-IFN) alfa-2b 1.5 ug/kg/week plus low-dose ribavirin administered for 48 weeks in participants with chronic hepatitis C virus (HCV) who are infected with HCV genotype 1 high viral load, and weigh 50 kg or less.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pegylated Interferon alfa-2b | Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks |
| DRUG | Ribavirin | Ribavirin 400 mg/day orally |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2008-05-30
- Last updated
- 2017-04-07
- Results posted
- 2012-01-18
Source: ClinicalTrials.gov record NCT00686777. Inclusion in this directory is not an endorsement.